We enable the acceleration of life science research
and development in the pursuit of improved human health
About Cellvera
Cellvera is a biopharmaceutical company focused on discovering, developing and commercializing oral therapies and monitoring tools to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleotide chemistry, biology, biochemistry and virology, Cellvera has built a nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).
Global Response Aid (GRA)
At the stage where COVID-19 was declared a pandemic, we quickly deployed a crew to start an initiative, that later became a full-fledged company called Global Response Aid. Alongside Agility which is one of the world’s leading logistics companies with a presence in 100 countries and annual turnover of $5BN.
PROJECTS
OUR TEAM
Abdulla Al Mansoori
Executive Director, MENA
Mary O’Brien
Chief Executive Officer
Dr. Alessandro Gadotti
Chief Operating Officer
Luca Longobardi
M&A Director
John White
General Counsel
NEWS
April 22, 2022
Cellvera Announce 2021 total sales of 100M$ and Audited Accounts with Revenues of $50M
April 22, 2022
World’s Largest Meta-Analysis of Favipiravir Data Demonstrates Significant Clinical Improvements in COVID-19 Patients
APR 11, 2022
Cellvera Supports Oxford University and the UK Department of Health and Social Care With Expansion of the PRINCIPLE Trial
Cellvera, a US commercial-stage biopharmaceutical company focused on developing and commercializing antiviral therapies to transform patients’ lives today, confirms $100M in sales for Favipiravir in 2021 and PCAOB 2021 audited accounts with $50M in revenues and EBITDA $12.1M.
The world’s largest meta-analysis conclusively revealed that Favipiravir significantly improved viral clearance rates in mild to moderate patients versus control groups 14 days after onset of symptoms (relative risk [RR] = 1.16; 95% confidence interval [CI]: 1.04, 1.30; P = 0.008)
Cellvera, a biopharmaceutical company focused on discovering and developing antiviral therapies across a broad spectrum of infectious diseases, holds exclusive worldwide rights directly to Qifenda 400mg, 800mg as well as the IV presentation and through its affiliates, Avigan 200mg. This broad-spectrum oral antiviral treatment targets COVID-19 and 11 different classes of infectious diseases.
February 28, 2022
Cofepris authorizes effective treatment against COVID-19
January 24, 2022
Cellvera Receives $20M Purchase Order for COVID-19 Oral Antiviral Avigan®
October 5, 2021
AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX).
A medicine that has been approved in more than 20 countries and prescribed to more than 5 million patients.
The US-based biopharmaceutical company, Cellvera , together with its local partner, Vinitori Comercializadora SA de CV, launched “QIFENDA 400MG” ( Favipiravir ) on the Mexican market. It is a highly effective oral antiviral tablet.
Cellvera, a global biopharmaceutical company developing and commercializing innovative antiviral therapies, and the Global Response Aid today announced a supply of millions of its COVID-19 oral antiviral Avigan® to Malaysia in the coming weeks.
DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement
September 29, 2021
AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics
AiPharma Global Holdings LLC ("AiPharma"), a private biopharmaceutical research, development, and commercialization company, and Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company.
September 23, 2020
Anti-influenza drug Avigan® TabletMeets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients
TOKYO, September 23, 2020—FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet”
